|
A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer Clinical research trials and A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer. A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer  A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer
A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer
For Condition: Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Non-Small Cell Lung Cancer, Stage IIIB or IV that is not amenable to either surgery of curative intent or radiation therapy - Tumor that can be measured by x-ray or scan - Adequate organ function Exclusion Criteria: - Inability to swallow capsules - Documented brain metastases - Prior chemotherapy or biological therapy for this disease
Total Enrollment:
Location and Contact Information:
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Hamburg, ,
Germany
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Oviedo, Asturias,
Spain
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Amsterdam, ,
Netherlands
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Pamplona, Navarra,
Spain
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Gauting, ,
Germany
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Boston, Massachusetts,
United States
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Rotterdam, ,
Netherlands
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Birmingham, Alabama,
United States
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Madrid, ,
Spain
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Kfar Saba, ,
Israel
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Toronto, Ontario,
Canada
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Badalona, Barcelona,
Spain
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Manhasset, New York,
United States
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Haifa, ,
Israel
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Montreal, Quebec,
Canada
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Durham, North Carolina,
United States
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Ottawa, Ontario,
Canada
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician". *Recruiting*
Houston, Texas,
United States
Recruiting
Additional Information:
Study ID Numbers: 4842;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00069875
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
2. Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
3. A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer
4. This study is to assess the efficacy and safety of ZD6474 in subjects with Non-small cell lung cancer.
5. OSI-774 (Tarceva) in Treating Patients with Stage III or Stage IV Non-Small Cell Lung Cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Ontario Clinical Trials
Other Ottawa Clinical Trials
A study with Gemzar, Cisplatin, and LY293111 in non-small cell lung cancer
|
|
|
|
|
|
|
|
